LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
The case, filed in the U.S. District Court for the District of New Jersey under the title Moon v. Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed ...
Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.
LONDON/SAN FRANCISCO (Reuters) – Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback